title: Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective.
abstract: OBJECTIVE
  The Finnish Diabetes Prevention Study (DPS) was a randomized intervention program that evaluated the effect of intensive lifestyle modification on the development of diabetes mellitus type 2 in patients with impaired glucose tolerance. As such, a program is demanding in terms of resources; it is necessary to assess whether it would be money well spent. This determination was the purpose of this study.
  
  
  METHODS
  We developed a simulation model to assess the economic consequences of an intervention like the one studied in DPS in a Swedish setting. The model used data from the trial itself to assess the effect of intervention on the risk of diabetes and on risk factors for cardiovascular disease. Results from the United Kingdom Prospective Diabetes Study were used to estimate the risk of cardiovascular disease and stroke. Cost data were derived from Swedish studies. The intervention was assumed to be applied to eligible patients from a population-based screening program of 60-year-olds in the County of Stockholm from which the baseline characteristics of the patients was used.
  
  
  RESULTS
  The model predicted that implementing the program would be cost-saving from the healthcare payers' perspective. Furthermore, it was associated with an increase in estimated survival of .18 years. Taking into consideration the increased consumption by patients due to their longer survival, the predicted cost-effectiveness ratio was 2,363 euro per quality-adjusted life-year gained.
  
  
  CONCLUSIONS
  Lifestyle intervention directed toward high-risk subjects would be cost-saving for the healthcare payer and highly cost-effective for society as a whole.
authors.affiliation: Karolinska Institutet, Stockholm, Sweden. peter.lindgren@healtheconomics.se
authors.forename: Peter
authors.initials: P
authors.lastname: Lindgren
authors.forename: Jaana
authors.initials: J
authors.lastname: Lindström
authors.forename: Jaakko
authors.initials: J
authors.lastname: Tuomilehto
authors.forename: Matti
authors.initials: M
authors.lastname: Uusitupa
authors.forename: Markku
authors.initials: M
authors.lastname: Peltonen
authors.forename: Bengt
authors.initials: B
authors.lastname: Jönsson
authors.forename: Ulf
authors.initials: U
authors.lastname: de Faire
authors.forename: Mai-Lis
authors.initials: ML
authors.lastname: Hellénius
mesh_terms: D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D005260:Female; D005387:Finland; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D040242:Risk Reduction Behavior
chemical_list: D005947:Glucose